ExeGi Management
[vc_team title=”Marc Tewey, MBA” css_animation_speed=”faster” css_animation_delay=”0″ image=”110″ subtitle=”Chief Executive Officer”]Marc Tewey serves Chief Executive Officer of ExeGi Pharma. Marc has significant expertise in live biotherapeutic, probiotics and rare disease sales and marketing, sales team leadership, business development, and strategic planning.
Marc’s experience includes commercial and development projects in oncology, gastroenterology, genetic and metabolic disorders, neonatology, medical foods and a variety of rare “Orphan” diseases. Prior to joining ExeGi Marc was CEO of Cambrooke Therapeutics a leader in the field of medical foods for rare metabolic disorders such as phenylketonuria. Prior to Cambrooke Marc was a founding partner at a startup rare disease company called Cerium Pharmaceuticals and Vice President of Sigma-Tau Pharmaceuticals, where he held a variety of positions over a 10 year period. At Sigma Tau, Marc was responsible for the development, implementation, and administration of commercial operations, strategies, and objectives encompassing sales, marketing, and project management. Marc has managed numerous major medical food and Rare Disease brands including Oncaspar (pegaspargase) for acute lymphoblastic leukemia, Depocyt for lymphomatous meningitis, Adagen for ADA-SCID and Glytactin for phenylketonuria. Marc holds an MBA and BA from Loyola University.[/vc_team]
[vc_team title=”Yamil Hernández, MS, MBA” css_animation_speed=”faster” css_animation_delay=”0″ image=”79″ subtitle=”Chief Business Officer”]Yamil Hernández serves as ExeGi’s Chief Business Officer, and is a dedicated and accomplished business development, alliance management, and program management professional. With over a decade of experience in the pharmaceutical industry specializing in Rare Diseases, Mr. Hernandez has a successful track record of managing, directing, and executing Business Development and Program Management activities and has extensive expertise in biologic and small molecule technology acquisitions, in/out-licensing, development, and commercialization collaborations.
In the late 90’s, Yamil joined Sigma-Tau Pharmaceuticals Inc., and held various roles of increased responsibility ultimately leading the Business Development and Project Management departments as Vice President where he was responsible for the acquisition, licensing, and program management of Rare Disease products and projects. Yamil was previously the Vice President of Business Development for Cerium Pharmaceuticals, Inc. which focuses exclusively on Rare Diseases.[/vc_team]
[vc_team title=”Conrad Shepard” css_animation_speed=”faster” css_animation_delay=”0″ image=”323″ subtitle=”Director, National Accounts”] Conrad Shepard serves as the Director of National Accounts for ExeGi Pharma, LLC. Conrad has more than 35 years in the pharmaceutical industry. Conrad manages the corporate accounts for both human and veterinary markets.
Before joining ExeGi Pharma, Conrad worked for Sigma-Tau Pharmaceuticals commercializing numerous brands in the fields of dialysis, family planning, and gastroenterology. Prior to Sigma Tau he worked for PDI as a District Sales Manager and Burroughs Wellcome Co. At Burroughs Wellcome he started as a Territory Representative before advancing to Training Representative, and finally Senior Medical Center Representative. His experiences at Wellcome included: infectious disease (antiviral-HIV/AIDS), oncology, kidney disease, arthritis and anesthesia. Conrad was involved in launching the first antiviral for HIV/AIDs, AZT. Conrad has had a successful track record in sales with many top awards and promotions in his career. Conrad has a BS degree in Biology (with an emphasis in Animal Sciences), and a minor in Chemistry and Math from Wichita State University.
[vc_team title=”Jeff Mendelsohn” css_animation_speed=”faster” css_animation_delay=”0″ image=”295″ subtitle=”Vice President, Animal Health”] Jeff Mendelsohn serves as Vice President of Animal Health for ExeGi Pharma. Jeff has more than 30 years of pharmaceutical and medical device sales and management in both the human and veterinary markets. Jeff was hired to manage the veterinary market for ExeGi Pharma in 2017 prior to the launch of Visbiome Vet in early 2018.
Before joining ExeGi Pharma, Jeff was Managing Partner of East Coast Medical Sales, a company focused on providing innovative therapies for pain management and regenerative medicine. Jeff has held various positions in the veterinary industry including National Sales Manager and Director of Equipment Sales for leading veterinary distribution companies. Jeff’s earlier experience including various sales, marketing and management positions in major pharmaceutical companies, including Syntex Laboratories, Novartis and Sankyo-Parke Davis. He brings a successful track record of hiring and managing field sales representatives, introducing new products to the medical and veterinary markets, cultivating KOLs, and strong project management skills. Jeff holds a BA from Roanoke College and a Master of Science from the University of Baltimore.